UPDATE: Cytokinetics Halted News Disseminated: Issues Update on BENEFIT-ALS, Says 58 Patients Received Placebo Instead of Drug

Cytokinetics, Incorporated (Nasdaq: CYTK ) announced today an update on the conduct of BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). BENEFIT-ALS is a Phase IIb, multinational, double-blind, randomized, placebo-controlled clinical trial designed